Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied.

Slides:

Advertisements

Similar presentations

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.

Advertisements

OIE standard-setting procedures - Focus on the Terrestrial & Aquatic Codes SPS workshop Geneva 17 October 2011 Dr Sarah Kahn Head International Trade Dept.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

CRICOS Provider No 00025B Engaging and Involving Staff and Senior Management in EEO Assessments UQs Experience.

CTSA KFC Meeting October 28, 2009 UIC Center for Clinical and Translational Science (CCTS): Biomedical Informatics Core.

LCPC RESEARCH ARM TO BE TRANSFORMED INTO A RESEARCH INCUBATOR.

Academic Senate 101 You Make It Happen! Catherine Cox President Mission College Academic Senate August, 2007 Adapted from ASCCC 101, presented at the ASCCC.

External Peer Review of the FDA Office of Regulatory Affairs Pesticide Program FDA Science Board Advisory Committee Meeting Nov. 4, 2005.

University of Vienna Rectorate – Office of the Rectorate May 30, 2008 Claudia Kögler University of Vienna, Office of the Rectorate.

Becker Grand Rounds: Wally Pellerite June 30, 2011.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The Life Cycle of an NIH Grant Application Alicia Dombroski, Ph.D. Deputy Director Division of Extramural Activities NIDCR.

The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006.

Introduction to Standard 2: Partnering with consumers Advice Centre Network Meeting Nicola Dunbar October 2012.

NSF ADVANCE Program Academic Careers in Engineering & Science (ACES) Lynn T. Singer (Provost’s Office), PI John Angus (Chemical Engineering), co-PI Mary.

Stuart D. Cook, M.D. Master Educators’ Guild A Commitment to Excellence in Education at UMDNJ Nicholas M. Ponzio, Ph.D. Professor of Pathology and Laboratory.

Loss Control Program Compliance Audits An overview of the purpose and procedures of program auditing.

Organizational Gaps in Reaching the “Desired State” Helen Winkle.

Monash University Library Quality Cycle EXCELLENCE AND DIVERSITY and LEADING THE WAY Monash University’s strategic framework and overall directions MONASH.

Promotion and Tenure Lois J. Geist, M.D. Associate Dean for Faculty Affairs and Development.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

1 Overview of Program. Representatives from the Medical and Nursing Schools of the 8 partner institutions Currently a group of 20 individuals – Growth.

3rd WG meeting, Brussels Proposed Plan for Governance of the Washington Group Prepared by: Jennifer Madans, Barbara Altman, Beth Rasch (USA); Renée Langlois.

President’s Office of Science and Technology Policy Deborah D. Stine Specialist in Science and Technology Policy December 3, 2008.

Scientific Merit Review René St-Arnaud, Ph.D. Shriners Hospital and McGill University CCAC National Workshop May 13, 2010, Ottawa (Ontario)

Strategic Clinical Networks Update October 2012 Drafted by Denise Mclellan.

The Ad Hoc Task Force on Internal Funding Fred Beard (Journalism), Bob Houser (Chemistry), & Joe Rodgers (Psychology) May, 2010 Internal Funding Recommendations.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Office of the Vice President for Research and Graduate Studies Office of Research Development and Proposal Coordination.

1 Corporate-level Evaluation on Gender Equality and Women’s Empowerment IFAD’s Office of Evaluation Informal Seminar Executive Board – 101st Session 13.

PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.

24 September 2009National Academies - BRDI1 Research Data and Information: New Developments at NIH Jerry Sheehan Assistant Director for Policy Development.

1 CAI-Asia China Project CAI-Asia China Project Inception Workshop October, 2005 Beijing PRC.

CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005.

NOAA Cooperative Institutes John Cortinas, Ph.D. OAR Cooperative Institute Program, Program Manager NOAA Cooperative Institute Committee, Chairperson.

DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.

Research Programs in the VA. 4 Distinct Program Areas Biomedical Laboratory Clinical Science Health Services Rehabilitation R&D.

Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.

Office of Research Oversight VHA Handbook VHA OPERATIONS ACTIVITIES THAT MAY CONSTITUTE RESEARCH Establishes standards and procedures for determining.

1Mobile Computing Systems © 2001 Carnegie Mellon University Writing a Successful NSF Proposal November 4, 2003 Website: nsf.gov.

External Peer Review of the FDA Office of Regulatory Affairs Pesticide Program FDA Science Board Advisory Committee Meeting March 31, 2006.

Rapid Response Team Nakissa Sadrieh, Ph.D. Associate Director for Research Policy and Implementation, OPS.

Update on Actions to Improve Regional Transportation Communications and Coordination During Incidents Prepared for the Transportation Planning Board Presented.

Educational Strategies Presented by: Christina Worrall Vice President, The Lewin Group, Inc PHDSC Annual Meeting March 18, 2004.

Coordinating Multiple Programs and Services Canadian School Health Conference April, 2008.

SPC Advisory Committee Training - TAC Fall 2015 Institutional Research President’s Office 1 Abridged from the SPC Advisory Committee Training on October.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

SPC Advisory Committee Training Fall 2015 Institutional Research President’s Office SPC 10/9/20151.

CBER Research: OBRR Office Site Visit Kathryn M. Carbone, MD Associate Director of Research CBER/FDA.

1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.

Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.

The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Peer Review of OBP Research Division of Monoclonal Antibodies

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Annual National Health Research Forum Ministry of Health 14 March 2013.

November | 1 CONTINUING CARE COUNCIL Report to Forum Year

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Import Safety Phase 2 Workgroup 1.

NSF Evaluator's Introduction Dee Hoffman, PhD IAB Meeting November 16, 2011.

Presentation on Strategic Plan for Monitoring and Evaluation 1386 – 1390.

Support in Department additional support staff Chair/A.D.

University Career Services Committee

Governance and Collaboration By-Laws

Participation of Patient Advocates in Community Advisory Boards A case-study: the HIV European Community Advisory Board (ECAB)

Department of Medicine Michael Farkouh, Vice-Chair Research michael

Foothill College Accreditation Self-Study Update

Preliminary Project Execution Plan

Presentation transcript:

Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied Pharmacology Research, OTR

Peer Review of Individual CDER Scientists Non-Lab Scientists Hired or Promoted to GS-14 or GS-15 via Expert or Master Reviewer Committees (Internal FDA Members) Mostly Non-Managers Promotions permanent, not periodically re-certified Title 42 or Title 38 (M.D.’s) also used for Non-Lab Personnel: No Committees; No Re-Certification Some Use of SBRS Systems for ongoing peer-review of individual senior scientists in all Centers have more similarities among the Centers than differences. Semi-Annual Management Review in All Cases.

CDER Laboratory Scientist Peer Review Committee: 50% members outside CDER: NIH,other FDA Centers Hiring or Promotion of Scientists to GS-14 or GS15 3-Year Renewable Promotion Senior Biomedical Research Service (SBRS) Agency-Wide Credentials Comm,External Consultants GS-15 and Above 4-Year Re-Certification Cycle Title 42: No Committees; No Re-Certification Peer Review of Individual CDER Lab Scientists

Peer-review of research programs varies across FDA Centers. In general, it is polarized into 2 different approaches. For the past 20 years, CBER and NCTR have evaluated lab research programs via an "academic" model, i.e., through site visits conducted by advisory committees. The other 5 units at FDA with lab programs (CDRH, CFSAN, CVM, ORA, and CDER) have used a "corporate" model, i.e., primary evaluation of research programs via internal Center (or ORA) management. At CDER, the internal review of lab and non-lab research programs has been occasionally supplemented by external review. However, external reviews have been episodic rather than formally established and regularly conducted. Peer Review of CDER Research Programs

Examples: Prior Ad Hoc External Reviews of CDER Programs FDA Science Board. Usually, one topic at a time, rather than full set of programs. Ad Hoc review by Generic Drug Advisory Committee, GDAC (predecessor of ACPS). Information Briefings for ACPS. Continuing the tradition begun in GDAC, ACPS receives periodic briefings (e.g., October 2004; March 2003) and occasional training sessions (e.g., May 2005; July 2001) regarding OTR lab programs. In each case, there are opportunities to comment and provide feedback, but the sessions not formally organized as a peer-review process.

Examples: Prior Ad Hoc External Reviews of CDER Programs {continued} Ad Hoc review of antiviral labs - actually, part of the charter of the Antiviral Drug Products Advisory Committee was to review the research programs of this lab. (Note: this lab has been abolished.) Ad Hoc review of cardiovascular lab support (Note: this lab has been abolished)

Examples of Ad Hoc Internal Reviews of CDER Programs [1] Annual Presentations to Center Director / Deputy Director [2] CDER Research Coordinating Committee, RCC Mission-oriented research at CDER not limited to lab programs. RCC established in various forms over last 15 years to provide advice to Center management regarding full range of internal research programs. Current RCC is chaired by the Deputy Center Director. Within OPS, research is also conducted in the immediate office, e.g., by the Informatics and Computational Safety Analysis Staff. Elsewhere in CDER, research is conducted in various units, especially the Office of Biometrics, Office of Drug Safety, Office of Information Management and Office of Clinical Pharmacology and Biopharmaceutics.

Funding and Peer Revew of CDER Research Programs [1] Funding for research, lab or non-lab, primarily determined by Office management. [2] In addition to funds from individual organizational budgets, some central funding is available from CDER’s “Review Science and Research (RSR)” program.  Funding areas are determined by CDER management  Proposals are reviewed by a committee of CDER scientists  Generally, funds are not for laboratory research, but foster activities such as database generation within review divisions

Funding and Peer Revew of CDER Research Programs External Sources of Research Funds [1] Other FDA sources of peer-reviewed funding for research are the FDA Office of Health Science Coordination and the FDA Office of Women’s Health.  Priorities for these programs are set by the management of the funding Office  Proposals are peer-reviewed for quality & relevance  Only internal FDA staff conduct the reviews.  Lab and non-lab proposals are accepted. [2] CRADAs and Inter-Agency Agreements